Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer(Unknown), David R. Gandara(University of California, Davis), Fairooz F. Kabbinavar(Kaiser Permanente), Joseph W. Leach(Minnesota Oncology), Shirish M. Gadgeel(Chinese University of Hong Kong), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Keunchil Park(The University of Texas MD Anderson Cancer Center), Daniel S. Chen(Synthetic Genomics (United States)), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Hande Turna(Istanbul University), Osvaldo Arén Frontera(Centro de Estudios Científicos), Pei He, Daniel Waterkamp, Alan Sandler(Chinese University of Hong Kong), Toyoaki Hida(Saitama International Medical Center), Fabrice Barlési(Hôpital Nord), Jong-Seok Lee(Seoul National University Bundang Hospital), Carlos H. Barrios(Eastern Cooperative Oncology Group), Jonathan Polikoff, Marcin Kowanetz, Marcus Ballinger, Filippo de Marinis(Carlo Forlanini Hospital)
Cited by 4,775
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k